Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors

被引:11
|
作者
Jaracz-Ros, Agnieszka [1 ]
Bernadat, Guillaume [2 ]
Cutolo, Pasquale [1 ]
Gallego, Carmen [1 ]
Gustavsson, Martin [3 ,8 ]
Cecon, Erika [4 ]
Baleux, Francoise [5 ]
Kufareva, Irina [3 ]
Handel, Tracy M. [3 ]
Bachelerie, Francoise [1 ]
Levoye, Angelique [6 ,7 ]
机构
[1] Univ Paris Saclay, INSERM, Inflammat Microbiome & Immunosurveillance, Clamart, France
[2] Univ Paris Saclay, CNRS, BioCIS, Chatenay Malabry, France
[3] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Jolla, CA USA
[4] Univ Paris, CNRS, INSERM, Inst Cochin, Paris, France
[5] Inst Pasteur, Unite Chim Biomol, Paris, France
[6] Univ Paris, INSERM, PARCC, Paris, France
[7] Univ Sorbonne Paris Nord, Bobigny, France
[8] Univ Copenhagen, Dept Biomed Sci, Blegdamsvej 3, Copenhagen 2200, Denmark
关键词
ACKR3; chemokine variants; CXCL12; CXCR4; GPCR signaling; pluridimensional efficacy; BETA-ARRESTIN; MOLECULAR-DYNAMICS; TUMOR-GROWTH; FACTOR-I; MIGRATION; ACTIVATION; DISSOCIATION; INHIBITION; REVEALS; AGONIST;
D O I
10.1002/JLB.2MA0320-383RR
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chemokines play critical roles in numerous physiologic and pathologic processes through their action on seven-transmembrane (TM) receptors. The N-terminal domain of chemokines, which is a key determinant of signaling via its binding within a pocket formed by receptors' TM helices, can be the target of proteolytic processing. An illustrative case of this regulatory mechanism is the natural processing of CXCL12 that generates chemokine variants lacking the first two N-terminal residues. Whereas such truncated variants behave as antagonists of CXCR4, the canonical G protein-coupled receptor of CXCL12, they are agonists of the atypical chemokine receptor 3 (ACKR3/CXCR7), suggesting the implication of different structural determinants in the complexes formed between CXCL12 and its two receptors. Recent analyses have suggested that the CXCL12 N-terminus first engages the TM helices of ACKR3 followed by the receptor N-terminus wrapping around the chemokine core. Here we investigated the first stage of ACKR3-CXCL12 interactions by comparing the activity of substituted or N-terminally truncated variants of CXCL12 toward CXCR4 and ACKR3. We showed that modification of the first two N-terminal residues of the chemokine (K1R or P2G) does not alter the ability of CXCL12 to activate ACKR3. Our results also identified the K1R variant as a G protein-biased agonist of CXCR4. Comparative molecular dynamics simulations of the complexes formed by ACKR3 either with CXCL12 or with the P2G variant identified interactions between the N-terminal 2-4 residues of CXCL12 and a pocket formed by receptor's TM helices 2, 6, and 7 as critical determinants for ACKR3 activation.
引用
收藏
页码:1123 / 1135
页数:13
相关论文
共 50 条
  • [21] Interaction and dynamics of chemokine receptor CXCR4 binding with CXCL12 and hBD-3
    Penfield, Jackson
    Zhang, Liqun
    COMMUNICATIONS CHEMISTRY, 2024, 7 (01):
  • [22] Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12
    Douglass, Stephen
    Meeson, Annette P.
    Overbeck-Zubrzycka, Dorota
    Brain, John G.
    Bennett, Miriam R.
    Lamb, Christopher A.
    Lennard, Thomas W. J.
    Browell, David
    Ali, Simi
    Kirby, John A.
    JOURNAL OF PATHOLOGY, 2014, 234 (01) : 74 - 85
  • [23] An Infernal Trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology
    Hattermann, Kirsten
    Mentlein, Rolf
    ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER, 2013, 195 (02) : 103 - 110
  • [24] Differential Estrogen-Regulation of CXCL12 Chemokine Receptors, CXCR4 and CXCR7, Contributes to the Growth Effect of Estrogens in Breast Cancer Cells
    Boudot, Antoine
    Kerdivel, Gwenneg
    Habauzit, Denis
    Eeckhoute, Jerome
    Le Dily, Francois
    Flouriot, Gilles
    Samson, Michel
    Pakdel, Farzad
    PLOS ONE, 2011, 6 (06):
  • [25] Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7
    Meyrath, Max
    Palmer, Christie B.
    Reynders, Nathan
    Vanderplasschen, Alain
    Ollert, Markus
    Bouvier, Michel
    Szpakowska, Martyna
    Chevigne, Andy
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2021, 4 (02) : 813 - 823
  • [26] The Chemokine Receptors CXCR4/CXCR7 and Their Primary Heterodimeric Ligands CXCL12 and CXCL12/High Mobility Group Box 1 in Pancreatic Cancer Growth and Development Finding Flow
    Shakir, Murtaza
    Tang, Daolin
    Zeh, Herbert J.
    Tang, Siu Wah
    Anderson, Carolyn J.
    Bahary, Nathan
    Lotze, Michael T.
    PANCREAS, 2015, 44 (04) : 528 - 534
  • [27] Diurnal expression of CXC receptors 4 (CXCR4) and CXC chemokine ligand 12 (CXCL12) in Pelteobagrus vachellii
    Qin, Chuanjie
    Memon, Nazakat Hussain
    Gong, Quan
    Shi, Qinchao
    Yang, Qingfa
    CHRONOBIOLOGY INTERNATIONAL, 2021, 38 (09) : 1299 - 1307
  • [28] Transcriptional and translational-uncoupling in regulation of the CXCL12 and its receptors CXCR4, 7 in THP-1 monocytes and macrophages
    Yu, Lu
    Yu, Liangli
    Quynhchi Pham
    Wang, Thomas T. Y.
    IMMUNITY INFLAMMATION AND DISEASE, 2018, 6 (01) : 106 - 116
  • [29] Differential expression of CXCL12 and CXCR4 during human fetal neural progenitor cell differentiation
    Peng, Hui
    Kolb, Ryan
    Kennedy, J. E.
    Zheng, Jialin
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2007, 2 (03) : 251 - 258
  • [30] Differential Expression of CXCL12 and CXCR4 During Human Fetal Neural Progenitor Cell Differentiation
    Hui Peng
    Ryan Kolb
    J. E. Kennedy
    Jialin Zheng
    Journal of Neuroimmune Pharmacology, 2007, 2 : 251 - 258